3 August 2026

CRISPR Therapeutics posts CASGEVY sales and new in vivo starts

CASGEVY generated second quarter 2026 revenue of $76 million; Phase 1 trials for CTX340 and CTX460 have been initiated.

The full briefing is in the app.